2. Apoptosis
  3. TNF Receptor
  4. Enavatuzumab

Enavatuzumab  (Synonyms: 依那妥组单抗; PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab))

目录号: HY-P99361 纯度: ≥95.0%
COA

摩尔计算器

Enavatuzumab (PDL192; ABT-361) 是一种人源化 IgG1 单克隆抗体，靶向 TNF 样细胞凋亡弱诱导剂受体 (TWEAK)。TWEAK (Fn14; TNFRSF12A) 是 TWEAK 受体 (TweakR) 的天然配体，可刺激多种细胞反应。Enavatuzumab 通过直接的 TweakR 信号和抗体依赖性细胞介导的细胞毒性 (ADCC) 诱导肿瘤生长抑制。Enavatuzumab 可以主动募集和激活骨髓效应细胞来杀死肿瘤细胞。Enavatuzumab 在体外和体内抑制各种人类 TweakR 阳性癌细胞系和异种移植物的生长。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

CAS No. : 1062149-33-0

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥3000
In-stock
5 mg ￥7500
In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Customer Review

Enavatuzumab 相关抗体

Top Publications Citing Use of Products

查看 TNF Receptor 亚型特异性产品:

查看所有亚型
TNFRSF1A/CD120a TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo [1] [2].

同型

Human IgG1 kappa
推荐同型对照抗体
种属

Humanized
体外研究
(In Vitro)

Enavatuzumab (0.1-1000 ng/mL; 4 小时) 在体外诱导效应细胞活化和肿瘤细胞杀伤[1]。
Enavatuzumab (10μg/mL; 24 小时) 导致免疫效应细胞向 SN12C 和 A375 肿瘤细胞的迁移显着增加[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Enavatuzumab 相关抗体:

Cell Viability Assay[1]

Cell Line: Renal carcinoma cell line SN12C, the melanoma cell line A375, the colorectal cancer cell lines HCT116 and DLD-1
Concentration: 0.1, 1, 10, 100, 1000 ng/mL
Incubation Time: 4 hours
Result: Showed potent tumor cell killing on all TweakR-positive tumor cells tested.
体内研究
(In Vivo)

Enavatuzumab (10mg/kg; 腹腔注射; 每周 3 次; 6, 7 或者 9 剂) 对不同的异种移植肿瘤表现出不同的抗肿瘤活性[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 6-week old SCID mice with SN12C or HCT116 or DLD-1 or A375 tumors[1]
Dosage: 10 mg/kg
Administration: IP; three times per week; 6 doses (DLD-1 model), 7 doses (SN12C model), 9 doses (A375 or HCT116 model)
Result: Some TweakR-expressing cells, such as SN12C and A375, were sensitive in vivo and in vitro.
Some TweakR-expressing cell lines, such as HCT116 and DLD-1, were not sensitive to enavatuzumab treatment in vivo, though both cell lines were effectively killed via ADCC in vitro.
Up-regulated the activation markers on splenocytes in SN12C tumor-bearing mice.
Clinical Trial
CAS 号
性状

液体

颜色

Colorless to light yellow

中文名称

依那妥组单抗
运输条件

Shipping with dry ice.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
纯度 & 产品资料

纯度: ≥95.0%

COA (264 KB)

抗体抑制剂使用指南 (1152 KB)
参考文献

Enavatuzumab 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Enavatuzumab1062149-33-0PDL192 ABT-361 Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)依那妥组单抗PDL 192PDL-192ABT361ABT 361ABT-361TNF ReceptorTumor Necrosis Factor ReceptorTNFRIgG1antibodyTNF-like weak inducer of apoptosisTWEAKFn14TNFRSF12ATweakRADCCmyeloid effectorcancerInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Enavatuzumab
目录号：
HY-P99361
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z